-
Information
iCFO Information Booth How can we help? -
Entrepreneur
PROOF Hard Ice Cream PROOF will be among the most highly recommended gourmet brands in the world -
Entrepreneur
STRATAFOLIO Total Commercial Property Management Platform -
EntrepreneurSoon Crypto Investing Automated & Easy
-
EntrepreneurGel Dynamics A Vetted Solution With A Global Market
-
EntrepreneurAdlore Introducing SenLore - A Novel Device to Treat and Monitor Diabetic Foot Ulcers
-
EntrepreneurCreative BioTherapeutics WE START WHERE OTHER THERAPIES FAIL FOR RECURRENT & DRUG RESISTANT CANCERS
-
EntrepreneurCommerceBlitz Optimizing Inventory and Distribution Operations for eCommerce Businesses
-
EntrepreneurSeekingSimple Improved health through better processed food choices to address food related disease for 230M in the US and the resulting $1.1T problem for healthcare payors
-
EntrepreneurTitin KM Biomedical Corporation THE FUTURE OF SHOULDER REHABILITATION
-
EntrepreneurVIC Tech A LIFE SCIENCE VENTURE STUDIO - Building a Healthy Future
-
EntrepreneurFuzelo The Future of Telehealth and Telefitness Technology
-
EntrepreneurKurve Therapeutics The Future of Systemic and Central Nervous System (CNS) Therapies - Bringing solutions to clinical unmet needs
-
EntrepreneurTorque3 Transformative Stroke Recovery
-
EntrepreneurMedAware Transforming patient safety
-
EntrepreneurIMEX USA Bank Where You Shop® Send, Spend, Save. Simple®
-
EntrepreneurAddimmune Addimmune’s sole purpose is to cure HIV. We believe it’s possible with gene and cell therapy.
Join us next time to meet Noel Greenberger!
Nob Hill Therapeutics is a healthcare startup that is developing new technologies and therapies for lung-related diseases that can’t be effectively treated today. These diseases impact millions of patients, and the annual market potential for several of these diseases is substantial (e.g., lung cancer - $30b, Cystic Fibrosis - $13b, Invasive fungal infections - $9b). Nob Hill has developed a new drug inhalation device platform that solves many disadvantages with today’s technologies and also is working on accompanying drug-device combination products that will serve as PoC for the technology (with addressable markets in the US of $1.75b annual sales). Nob Hill’s team is highly experienced with developing and commercializing respiratory products (combined experience of 100+ years).